Revenue Breakdown
Composition ()
No data
Revenue Streams
Takeda Pharmaceutical Co Ltd (TAK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Gastrointestinal diseases, accounting for 31.8% of total sales, equivalent to JPY 353.49B. Other significant revenue streams include Plasma derivatives and Rare diseases. Understanding this composition is critical for investors evaluating how TAK navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Takeda Pharmaceutical Co Ltd maintains a gross margin of 54.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.65%, while the net margin is 8.70%. These profitability ratios, combined with a Return on Equity (ROE) of 1.50%, provide a clear picture of how effectively TAK converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TAK competes directly with industry leaders such as RDY and NVO. With a market capitalization of $58.26B, it holds a significant position in the sector. When comparing efficiency, TAK's gross margin of 54.91% stands against RDY's 53.63% and NVO's 80.86%. Such benchmarking helps identify whether Takeda Pharmaceutical Co Ltd is trading at a premium or discount relative to its financial performance.
